These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16759043)

  • 1. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
    Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
    Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes.
    Trepanier J; Tanner JE; Momparler RL; Le ON; Alvarez F; Alfieri C
    J Viral Hepat; 2006 Feb; 13(2):131-8. PubMed ID: 16436131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the discovery of small molecule therapies for HCV.
    Myles DC
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):411-6. PubMed ID: 11727306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and successes in developing new therapies for hepatitis C.
    De Francesco R; Migliaccio G
    Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotide-based strategies to inhibit human hepatitis C virus.
    Martinand-Mari C; Lebleu B; Robbins I
    Oligonucleotides; 2003; 13(6):539-48. PubMed ID: 15025918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future therapy of hepatitis C.
    McHutchison JG; Patel K
    Hepatology; 2002 Nov; 36(5 Suppl 1):S245-52. PubMed ID: 12407600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future options for the management of hepatitis C.
    Davis GL; Nelson DR; Reyes GR
    Semin Liver Dis; 1999; 19 Suppl 1():103-12. PubMed ID: 10349698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute hepatitis C: prevention and treatment.
    Ozaras R; Tahan V
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and development of small molecule HCV antivirals.
    Ni ZJ; Wagman AS
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C: changing genotype distribution with important implications for patient management.
    van Soest H; Boland GJ; van Erpecum KJ
    Neth J Med; 2006 Apr; 64(4):96-9. PubMed ID: 16609154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.